AKTing on XPO1 inhibition in AML

被引：0
|
作者：
Goellner, Stefanie [1 ]
Mueller-Tidow, Carsten [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
[2] European Mol Biol Lab, Mol Med Partnership Unit, Heidelberg, Germany
[3] Heidelberg Univ, Heidelberg, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
来源：
NATURE CANCER | 2022年 / 3卷 / 07期
关键词：
NUCLEAR EXPORT; C/EBP-BETA; EXPRESSION; CRM1;
D O I：
10.1038/s43018-022-00395-w
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Inhibition of XPO1-mediated nuclear export by selinexor represents a promising therapeutic strategy in acute myeloid leukemia. Because XPO1 is not specific for tumor-suppressive proteins, selinexor may also activate pro-oncogenic processes. A study now shows that inhibition of selinexor-induced, purinergic receptor-mediated AKT activation potentiates its anti-leukemic activity.
引用
收藏
页码：787 / 789
页数：3
相关论文
共 50 条
  • [21] XPO1 and BRAF Inhibition Synergize and Modulate pRb, Survivin and ERK in Melanoma
    Fragomeni, R. A. Salas
    Cusack, J. C.
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S91 - S91
  • [22] Redirecting traffic using the XPO1 police
    Abraham, Sheela A.
    Holyoake, Tessa L.
    BLOOD, 2013, 122 (17) : 2926 - 2928
  • [23] Melphalan and XPO1 inhibition are synergistic in pre-clinical models of multiple myeloma
    Turner, Joel G.
    Dawson, Jana L.
    Sullivan, Daniel M.
    CANCER RESEARCH, 2016, 76
  • [24] XPO1 Inhibitor Approved for Multiple Myeloma
    Dolgin, Elie
    CANCER DISCOVERY, 2019, 9 (09) : 1150 - 1151
  • [25] Autophagy modulates glioblastoma cell sensitivity to Selinexor-mediated XPO1 inhibition
    Tang, Yongjian
    Sprinzen, Lisa
    Terada, Yukinori
    Kiang, Karrie M.
    Li, Chuntao
    Zeng, Yu
    Liu, Fangkun
    Zhou, Hongshu
    Liang, Xisong
    Zhang, Jianzhong
    Pieper, Russell O.
    Chen, Bo
    Zhang, Liyang
    NEURO-ONCOLOGY, 2025,
  • [26] Inhibiting the Nuclear Exporter XPO1 and the Antiapoptotic Factor BCL2 Is Synergistic in XPO1 Mutant and Wildtype Lymphoma
    Owusu-Ansah, Frank
    Afaghani, Jumana
    Lee, Stanley
    Taylor, Justin
    BLOOD, 2020, 136
  • [27] The Synergistic Effect of Melphalan and XPO1 Inhibition in Pre-Clinical Models of Multiple Myeloma
    Cui, Yan
    Turner, Joel G.
    Dawson, Jana L.
    Gomez, Juan A.
    Shain, Kenneth H.
    Meads, Mark B.
    Baloglu, Erkan
    Dalton, William S.
    Nishihori, Taiga
    Sullivan, Daniel M.
    BLOOD, 2016, 128 (22)
  • [28] SELINEXOR Exportin-1(XPO1) inhibitor Oncolytic
    Riaz, W.
    Burke, N.
    Mahipal, A.
    DRUGS OF THE FUTURE, 2014, 39 (10) : 685 - 692
  • [29] XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A
    Miyake, Takahito
    Pradeep, Sunila
    Wu, Sherry Y.
    Rupaimoole, Rajesha
    Zand, Behrouz
    Wen, Yunfei
    Gharpure, Kshipra M.
    Nagaraja, Archana S.
    Hu, Wei
    Cho, Min Soon
    Dalton, Heather J.
    Previs, Rebecca A.
    Taylor, Morgan L.
    Hisamatsu, Takeshi
    Kang, Yu
    Liu, Tao
    Shacham, Sharon
    McCauley, Dilara
    Hawke, David H.
    Wiktorowicz, John E.
    Coleman, Robert L.
    Sood, Anil K.
    CLINICAL CANCER RESEARCH, 2015, 21 (14) : 3286 - 3297
  • [30] Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma
    Nakayama, Robert
    Zhang, Yi-Xiang
    Czaplinski, Jeffrey T.
    Anatone, Alex J.
    Sicinska, Ewa T.
    Fletcher, Jonathan A.
    Demetri, George D.
    Wagner, Andrew J.
    ONCOTARGET, 2016, 7 (13) : 16581 - 16592
12345